Which daily injected agent is associated with increasing uric acid levels as a side effect?

• A. Romosozumab
• B. Abaloparatide
• C. Teriparatide
• D. Calcitonin

Answer: (C)

Teriparatide is the correct answer because it is known to be associated with increases in serum uric acid levels as a side effect. Teriparatide is a recombinant form of parathyroid hormone used to treat osteoporosis by stimulating bone formation. While it effectively increases bone density, one of the metabolic consequences can be the elevation of uric acid levels due to increased bone turnover and consequent release of uric acid from the breakdown of bone tissue.

Other agents like Romosozumab, Abaloparatide, and Calcitonin do not have this side effect related to uric acid levels. Romosozumab is a monoclonal antibody that works on bone metabolism; it does not directly influence uric acid levels. Abaloparatide is another treatment that mimics parathyroid hormone, but it is not typically associated with increased uric acid. Calcitonin, which works to inhibit osteoclast activity, does not have a known impact on uric acid levels either. Therefore, the specific mechanism of action and metabolic effects of teriparatide make it the agent that is associated with increased uric acid levels.